Are Heart Failure Management Recommendations and Guidelines Followed in Laboratory Medicine in Europe and North America? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study
| Autor: | Paul O. Collinson, Kari Pulkki, Ana Stavljenić-Rukavina, Kristin M. Aakre, Robert H. Christenson, Hannsjörg Baum, Christopher J. Duff, Angelika Hammerer-Lercher, Janne Suvisaari, Marja P. van Dieijen-Visser, Päivi Laitinen, Michel Langlois, Sanja Stankovic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.drug_class Medical laboratory General Medicine Guideline 030204 cardiovascular system & hematology University hospital medicine.disease 03 medical and health sciences 0302 clinical medicine Heart failure Emergency medicine Natriuretic peptide Medicine media_common.cataloged_instance 030212 general & internal medicine European union business Intensive care medicine Decision limit heart failure guidelines markers natriuretic peptides laboratory medicine media_common |
| Popis: | Background The aim of this survey was to investigate how well heart failure (HF) guidelines for use of natriuretic peptides (NPs) have been implemented in laboratory practice in Europe and North America. Methods In 2013 and 2014, a web-based questionnaire was distributed via North American and European biochemical societies. Questions covered assay performed, reason for method choice, decision limits for HF, and laboratory accreditation status. Results There were 442 European Union and 91 North American participating laboratories with response rates of 50% and 64% from major or university hospitals, respectively. NP measurements were offered in 67% of European Union and 58% of North American respondents. N-terminal pro–B-type natriuretic peptide (NT-proBNP) was most widely used in Europe (68%) and B-type natriuretic peptide (BNP) was more commonly used (58%) in North America. The most frequent reason for use of a specific assay was the availability of instruments that measure either NT-proBNP (51%) or BNP (67%). For diagnosis of acute HF, NT-proBNP decision limits were diverse; age-dependent limits based on the 2012 European Society of Cardiology (ESC) recommendations were used in only 17% of European sites and 26% of North American sites. For BNP, the guideline-recommended acute HF decision limit of 100 ng/L was better adhered to in Europe (48%) and North America (57%). Surprisingly, similar decision limits were stated for acute and chronic HF by >50% of respondents. Conclusions NP measurement for HF diagnosis was available in >50% of responding laboratories. However, guideline recommended cutoff values for both acute and chronic HF were still implemented in |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|